Release Date: March 14, 2017
Expiration Date: March 14, 2018
Media: Print with online posttest, evaluation, and request for credit
This activity is designed to inform physicians about emerging therapies for patients with hepatocellular carcinoma.
Instructions for Participation/How to Receive Credit:
This activity is directed toward medical oncologists, primary care physicians, nurses, and nurse practitioners who treat and/or manage patients with hepatocellular carcinoma. Surgical oncologists, radiation oncologists, pathologists, internists, fellows, physician assistants, and other healthcare providers are also invited to participate.
After participating in this CME/CE activity, learners should be better prepared to:
Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.
Ghassan K. Abou-Alfa, MD
Memorial Sloan Kettering Cancer
New York, NY
Disclosure: Grant/Research Support: Amgen, Astra Zeneca, BMS, Bayer, CASI, Celgene, Chugai, Exelixis, Genentech, Incyte, Mabvax, Medimmune, Momenta, OncoMed Pharmaceuticals, Roche, Vicus Therapeutics Consultant: Aduro Biotech Agios, Aslan, Astellas Pharma US, Astra Zeneca, Bayer, Blueprint, Boston Scientifc, Bristol-Myers Dquibb, Celgene, CASI, Delcath, Eisai, Gilead, Halozyme, Integragen, Ipsen, Janssen, Merck, Medimmune, Merrimack, New B Innovation, NewLink Genetics, Onxeo, Roche, Sanofi-Aventis, Servier, Silenseed, Sillajen, Sirtex, Vaxxim, Vicus Therapeutics, Westhaven.
The staff of Physicians’ Education Resource®, LLC (PER®), and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
It is the policy of PER® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.
This activity is funded by PER®
This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC.
Contact information for questions about the activity:
Physicians’ Education Resource®, LLC
2 Clarke Drive
Cranbury, NJ 08512
Phone: (888) 949-0045